Abstracts Archive - Page 942 of 2425 - ACR Meeting Abstracts

Abstract Number: 2756 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, David Walsh ⁵, Alexander White ⁶, Satoru Nakajo ⁷, Robert Fountaine ⁸, Anne Hickman ⁸, Glenn Pixton ⁹, Lars Viktrup ¹⁰, Mark T. Brown ⁸, Christine R. West ⁸ and Kenneth M. Verburg ⁸, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁶Progressive Medical Research, Port Orange, FL, ⁷Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Morrisville, NC, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies,…
Abstract Number: 2757 • 2019 ACR/ARP Annual Meeting
Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)
Zoe Paskins ¹, Kieran Bromley ², Martyn Lewis ², Gemma Hughes ², Emily Hughes ², Andrea Cherrington ², Alison Hall ², Melanie Holden ³, Raymond Oppong ⁴, Kay Stevenson ², Ajit Menon ⁵, Philip Roberts ⁶, George Peat ², Clare Jinks ⁷, Nadine Foster ², Christian Mallen ⁸ and Edward Roddy⁹, ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²Keele University, Keele, United Kingdom, ³Research Institute for Primary Care and Health Sciences and Keele CTU, Keele University, Keele, England, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom, ⁶University Hospitals North Midlands NHS Trust, Stoke-on-Trent, United Kingdom, ⁷Research Institute for Primary Care and Health Sciences, Keele University, Keele, England, United Kingdom, ⁸Research Institute for Primary Care and Health Sciences, Keele University, UK, Keele, United Kingdom, ⁹Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom
Background/Purpose: Evidence of the effectiveness of intra-articular corticosteroid injection for hip osteoarthritis (OA) is limited and conflicting. The HIT trial compared the clinical effectiveness of…
Abstract Number: 2758 • 2019 ACR/ARP Annual Meeting
Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis
Ben Hudson ¹, Leslie Toop ², Jonathan Williman ¹, Gary Hooper ¹, Dee Mangin ¹, John Alchin ¹, Browyn Thompson ¹ and Lisa Stamp¹, ¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²UNiversity of Otago, Chirstchurch, Christchurch, Canterbury, New Zealand
Background/Purpose: Osteoarthritis (OA) is the most common joint disease and is a major cause of pain and disability There is currently no cure for OA…
Abstract Number: 2759 • 2019 ACR/ARP Annual Meeting
Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy
Liana Fraenkel¹, Eugenia Buta ², Joseph Goulet ³, Matthew Brennan ³, Alicia Heapy ³ and Lisa Suter ³, ¹Yale School of Medicine and VA Connecticut Healthcare System, New Haven, ²Yale University/VA CT Healthcare System, New Havne, ³Yale University/VA CT Healthcare System, New Haven
Background/Purpose: NSAIDs are associated with uncertain long-term benefits and significant toxicity in patients with knee osteoarthritis (OA). Our objective was to evaluate if discontinuing NSAIDs…
Abstract Number: 2760 • 2019 ACR/ARP Annual Meeting
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Michael Billard ¹, John Todhunter ¹, Margaret Fleming ¹, Tim Warneke¹, Yuhui Qiu ², Nhu Ly ², William Aronstein ² and William Moore ¹, ¹Vizuri Health Sciences, LLC, Columbia, MD, ²CTI Clinical Trial & Consulting, Covington, KY
Background/Purpose: There is considerable unmet medical need for an osteoarthritic knee pain (OAKP) treatment that does not require regular daily use, does not carry gastrointestinal…
Abstract Number: 2761 • 2019 ACR/ARP Annual Meeting
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
Hans Guehring¹, Jeffrey Kraines ², Flavie Moreau ², Benjamin Daelken ¹, Christoph Ladel ¹, Wolfgang Wirth ³, Philip G Conaghan ⁴, Felix Eckstein ⁵ and Marc C. Hochberg ⁶, ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Paracelsus Medical University, Salzbury, Austria, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Paracelsus Medical University, Salzburg, Austria, ⁶University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Results from the 5-year Phase II FORWARD study showed significant dose-dependent modification of total femorotibial joint (TFTJ) cartilage thickness change with sprifermin at 2…
Abstract Number: 2762 • 2019 ACR/ARP Annual Meeting
The Preparation and Recovery Experience from Total Knee Replacement of Patients with Osteoarthritis: A Qualitative Study
Iris Navarro-Millan¹, Sarah Young ², Geyanne Lui ¹, Marianna Frey ³, Janey Peterson ¹, Susan Goodman ⁴, Monika Safford ¹ and Lisa Mandl ⁵, ¹Weill Cornell Medicine, New York, ²Binghamton University, Binghamton, ³Hospital for Special Surgery, New York, NY, New York, ⁴Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Up to 30% of patients may have persistent pain post-total knee arthroplasty (TKA). One possible approach to improve these outcomes is to optimize muscle…
Abstract Number: 2763 • 2019 ACR/ARP Annual Meeting
What Disease Do You Have? – Assessment and Predictors of Accurate Illness Naming in Rheumatology
Jacob Meindertsma¹, Kara Harrison ¹, Nicholas Lucchesi ¹ and Adam Carlson ¹, ¹University of Virginia, Charlottesville, VA
Background/Purpose: Shared decision making remains central to the effective treatment of many rheumatologic conditions and is most appropriate when the patient and physician agree on…
Abstract Number: 2764 • 2019 ACR/ARP Annual Meeting
Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding…
Abstract Number: 2765 • 2019 ACR/ARP Annual Meeting
Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis
Matt Allsion¹, Michael McMorris ², Dhiren Patel ² and B Stephen Burton ³, ¹Pack Health, Birmigham, AL, ²Pack Health, Birmingham, ³Pack Health, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. RA has a significant negative impact on the ability to perform daily…
Abstract Number: 2766 • 2019 ACR/ARP Annual Meeting
Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment
Dennis Turk ¹, Marco Boeri², Lucy Abraham ³, Brett Hauber ⁴, Joanna Atkinson ³, Andrew Bushmakin ⁵, Joseph Cappelleri ⁵, Leo Russo ⁶, Lars Viktrup ⁷ and David Walsh ⁸, ¹University of Washington, Seattle, ²RTI Health Solutions, Belfast, Northern Ireland, United Kingdom, ³Pfizer, LTD, Surrey, England, United Kingdom, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer, Inc., Collegeville, PA, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom
Background/Purpose: Monoclonal antibodies that inhibit nerve growth factor (NGF-abs) may offer an alternative to current nonsteroidal anti-inflammatory drug (NSAID) and opioid treatments for osteoarthritis (OA)…
Abstract Number: 2767 • 2019 ACR/ARP Annual Meeting
Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed
Kelly O'Neill¹, Cynthia Crowson ², Dana Symons ³, Pamela Sinicrope ⁴, Elena Myasoedova ⁴, Martha Bock ⁴, Jon Tilburt ⁴ and John Davis ⁴, ¹Rheumatoid Patient Foundation, Inc., Winter Springs, FL, ²Mayo Clinic Rochester, Rochester, ³Rheumatoid Patient Foundation, Inc., Rockford, MI, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Treat-to-target is a guiding principle in the management of rheumatoid arthritis (RA), and randomized clinical trials demonstrate its value in improving outcomes. However, implementation…
Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo¹, Israel Nieto-Gañán ², Cristina Sobrino ³, Victoria Navarro-Compán ⁴, Ana Martínez-Feito ⁵, Carlota García-Hoz ⁶, Paloma Lapuente-Suanzes ², javier Bachiller ³, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ³, Garbiñe Roy ², Mónica Vázquez Díaz ³, Alejandro Balsa ⁷, Luisa María Villar ², Dora Pascual-Salcedo ¹, Eulalia Rodríguez-Martín ² and Chamaida Plasencia ⁷, ¹Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ³Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁶Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
Abstract Number: 2769 • 2019 ACR/ARP Annual Meeting
The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis
Sandrine Isaac ¹, Alejandro Artacho ¹, Renuka Nayak ², Steven B. Abramson ³, Margaret Alexander ², Imhoi Koo ⁴, Pamela Rosenthal ⁵, Peter Izmirly ⁶, Andrew Patterson ⁷, Antonio Pineda ⁸, Leonor Puchades-Carrasco ⁸, Peter Turnbaugh ², Carles Ubeda ⁹ and Jose Scher¹⁰, ¹FISABIO, Valencia, Spain, ²UCSF, San Francisco, ³NYU School of Medicine and NYU Langone Orthopedic Hospital, New York City, NY, ⁴Pennsylvania State University; Penn State · Huck Institutes of Life Sciences, University Park, PA, ⁵NYU Langone Orhopedic Hospital, New York, ⁶NYU School of Medicine, New York, ⁷Penn State, University Park, PA, ⁸Centro de Investigación Príncipe Felipe/Instituto de Investigación Sanitaria La Fe, Valencia, Spain, ⁹Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ¹⁰New York University School of Medicine, New York, NY
Background/Purpose: Early treatment initiation in rheumatoid arthritis (RA) is fundamental to avoid chronic joint destruction and disability. Despite remarkable advances in RA therapeutics, oral methotrexate…
Abstract Number: 2770 • 2019 ACR/ARP Annual Meeting
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission
Joanna Kedra¹, Philippe Dieudé ², Hubert Marotte ³, Alexandre Lafourcade ⁴, Emilie Ducourau ⁵, Thierry Schaeverbeke ⁶, Aleth Perdriger ⁷, Martin SOUBRIER ⁸, Jacques Morel ⁹, Arnaud Constantin ¹⁰, Emmanuelle Dernis ¹¹, Valérie Royant ¹², Jean-Hugues Salmon ¹³, Thao Pham ¹⁴, Jacques-Eric Gottenberg ¹⁵, Edouard Pertuiset ¹⁶, Maxime Dougados ¹⁷, Valérie Devauchelle Pensec ¹⁸, Philippe Gaudin ¹⁹, gregoire Cormier ²⁰, Philippe Goupille ²¹, Xavier Mariette ²², Francis Berenbaum ²³, Didier Alcaix ²⁴, Sid-Ahmed Rouidi ²⁵, Jean-Marie Berthelot ²⁶, Agnès Monnier ²⁷, Christine Piroth ²⁸, Frédéric Lioté ²⁹, Vincent Goeb ³⁰, Cécile Gaujoux-Viala ³¹, Isabelle Chary-Valckenaere ³², David Hajage ⁴, Florence Tubach ³³ and Bruno Fautrel ³⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ³University Hospital, St Etienne, France, ⁴Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ⁵Rheumatology Department, CHR Orléans, Orléans, France, ⁶FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁷Rheumatology department, Rennes University Hospital, France, Rennes, France, ⁸CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ⁹CHU MONTPELLIER, MONTPELLIER, France, ¹⁰Hôpital Pierre-Paul Riquet, Toulouse, France, ¹¹Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹²Rheumatology Department, Chartres Hospital, Chartres, France, ¹³Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ¹⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁶Rheumatology Department, Pontoise Hospital, Pontoise, France, Pontoise, France, ¹⁷Cochin Hospital, Paris, France, ¹⁸University Hospital of Brest, Brest, France, ¹⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ²⁰CHD Vendée, La Roche sur Yon, France, ²¹Tours University-Hospital, Tours, France, Tours, France, ²²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ²³Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France, ²⁴Rheumatology Department, Le Havre Hospital, Le Havre, ²⁵Rheumatology Department, Dreux, France, ²⁶University Hospital, Nantes, France, ²⁷Internal Medicine Department, CH Côte Basque, Bayonne, France, ²⁸Rheumatology Department, Dijon Hospital, Dijon, France, ²⁹Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ³⁰Rheumatology Department, Amiens University Hospital, Amiens, France, ³¹Nîmes University Hospital, Nîmes, France, ³²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ³³Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARD) tapering is proposed by clinical practice guidelines in rheumatoid arthritis (RA) patients in sustained remission. However, no randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].